Detalles de la búsqueda
1.
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
Int J Cancer
; 153(1): 133-140, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36752579
2.
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Br J Cancer
; 129(7): 1071-1082, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568037
3.
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.
BMC Med
; 21(1): 234, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37400832
4.
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study.
Future Oncol
; 18(21): 2643-2653, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608115
5.
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Br J Cancer
; 116(11): 1425-1435, 2017 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28441382
6.
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
Cancer Lett
; 593: 216968, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38788968
7.
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Nat Commun
; 15(1): 2287, 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38480701
8.
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Cancer Treat Rev
; 115: 102530, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898352
9.
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
NPJ Breast Cancer
; 9(1): 48, 2023 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37258566
10.
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Cancers (Basel)
; 15(23)2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067406
11.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Eur J Cancer
; 195: 113404, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37948842
12.
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Res Sq
; 2023 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37502925
13.
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
Front Immunol
; 14: 1289434, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304255
14.
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Biochim Biophys Acta Rev Cancer
; 1877(6): 188810, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36202311
15.
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC.
Lung Cancer
; 174: 36-44, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302311
16.
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer.
Appl Immunohistochem Mol Morphol
; 30(9): 600-608, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36083147
17.
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Crit Rev Oncol Hematol
; 172: 103649, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35259486
18.
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer.
Biomolecules
; 12(10)2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291602
19.
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Cancers (Basel)
; 14(23)2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497292
20.
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Cancer Immunol Res
; 10(7): 829-843, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35561311